11/09/2026 Handa Secures final US FDA approval for OMCAZIO™ Cabozantinib capsules Immutep refocuses eftilagimod alfa development on PD-L1-negative (CPS <1) HNSCC and neoadjuvant STS following TACTI-004 discontinuation SERENA-4 Phase 3 trial of Etcamah + palbociclib missed its primary PFS endpoint in 1L ER+/ HER2- advanced breast cancer Handa Secures final US FDA approval for OMCAZIO™ Cabozantinib capsules (Ref) Handa Pharmaceuticals has received final US FDA approval for OMCA

04/09/2026 US FDA grants accelerated approval for camizestrant combination as first-line treatment of ESR1-mutated advanced ER+ Breast cancer US FDA grants accelerated approval for camizestrant combination as first-line treatment of ESR1-mutated advanced ER+ Breast cancer (Ref) AstraZeneca announced that the US FDA has granted accelerated approval for Etcamah (camizestrant; next-generation oral SERD and complete ER antagonist) in combination with a CDK4/6 inhibitor for first-